Mayinglong Pharmaceutical Group Co., Ltd. Provides Earnings Guidance for the Year 2019
January 20, 2020
Share
Mayinglong Pharmaceutical Group Co., Ltd. provided earnings guidance for the year 2019. The company predicts a year-on-year increase of between 90% and 110% in its net profit belonging to shareholders of the listed company in 2019. The net profit belonging to shareholders of the listed company after excluding extraordinary profit and loss in 2019 will increase by between 5% and 15% compared with the same period of the year before.
Mayinglong Pharmaceutical Group Co., Ltd. is a China-based company, principally engaged in pharmaceutical production, retailing and wholesaling businesses. The Company's pharmaceutical products are classified as drugs for hemorrhoid, including diosmin tablets, suppositories, pastes and granules, among others; drugs for cough, including levodropropizine oral solution and compound glycyrrhiza oral solution, as well as drugs for skin injuries, including products such as erythromycin ointment. The Company also provides specialty drugs. The Company is also engaged in the production and distribution of eye cream products with the brand named Mayinglong BaBao, as well as the provision of hospital clinical service. The Company distributes its products mainly in domestic markets.
MAYINGLONG PHARMACEUTICAL GROUP CO., LTD. 